Bio-ReCell
- Company typePrivate
- Founded2018
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bio-ReCell does
Bio-ReCell d.o.o. is a privately held Slovenian life-sciences company founded in 2018, headquartered in Ljubljana-Dobrunje in a 1,700 m² facility that includes a certified BSL-2 microbiology laboratory. The company develops and commercializes magnet-free, antibody-bound biocomposite cell processing technology for cell and gene therapy manufacturing, anchored on three core products: the Atract™ T-Cell Activation Kit (V1 with CD3/CD28 and V2 with CD2/CD3/CD28, sold in 10 mg and 50 mg formats), the Neptune™ T-Cell Separation Kit (gravity-based negative selection for CD3+ T-cell isolation), and the Revive™ SVF Isolation Device (a closed, automated system for isolating stromal vascular fraction from adipose tissue for regenerative medicine). The underlying platform relies on covalently bonded antibodies on non-phagocytisable particles, which the company positions as eliminating magnetic beads, centrifugation, and residual contamination in cell processing workflows.
The company sells consumable kits and devices on a quote-based, pay-as-you-go model through a global distributor network that, as of mid-2026, covers the United Kingdom (Caltag Medsystems), Japan (Filgen), the United States (Cosmo Bio USA), India (Ross Biotech, Cytocare, Cell Bioasis), and broader Asia-Pacific (Api Asia), supplemented by direct sales for enterprise accounts. It serves academic institutions, biotechnology companies, contract research organizations, and translational/regenerative medicine researchers developing CAR-T and other cell therapies, with claimed customer outcomes of a 9-day reduction in per-batch processing and quality control time and a 10% reduction in overall manufacturing costs. Revenue and headcount are not publicly disclosed; the only external capital referenced is a €299,988.37 EU Recovery and Resilience Facility grant awarded in November 2023 for an automated mesenchymal stem cell separation project, and the company has a UK subsidiary (Bio-ReCell LTD). Leadership is anchored by CEO Dr. Luka Fajs, CFO Barbara Vtič Vraničar, and a scientific advisory board that includes Prof. Mark Lowdell, Prof. Frank Barry, Dr. Shannon Eaker, and the late co-founder Prof. Stephen Minger.
Bio-ReCell firmographics
Firmographics- Name
- Bio-ReCell
- Legal name
- Bio-ReCell d.o.o.
- Website
- https://bio-recell.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Where Bio-ReCell is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Bio-ReCell business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- T-Cell Activation Kit Sales: Bio-ReCell generates revenue through the sale of its proprietary Atract™ T-Cell Activation Kits, available in multiple formats (V1 and V2 versions) with different activation capacities for PBMC processing.
- T-Cell Separation Kit Sales: Revenue from Neptune™ Kit sales for T-cell separation, sold as a complete kit with biocomposites, strainers, and buffer for magnet-free cell separation.
- SVF Isolation Device Sales: Revenue from Revive™ SVF Isolation Device sales, a closed automated system for regenerative medicine applications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Atract™ Kit V1 (CD3/CD28) - 4x 10 mg format |
| Unit Pricing | Pay-as-you-go | Atract™ Kit V1 (CD3/CD28) - 4x 50 mg format |
| Unit Pricing | Pay-as-you-go | Atract™ Kit V2 (CD2/CD3/CD28) - 4x 10 mg format |
| Unit Pricing | Pay-as-you-go | Atract™ Kit V2 (CD2/CD3/CD28) - 4x 50 mg format |
| Unit Pricing | Pay-as-you-go | Neptune™ Kit |
Go-to-market motion2 records
Distribution channels6 records
Marketing channels6 records
Bio-ReCell product offering
Product offeringCore offering
Bio-ReCell develops and sells magnet-free, antibody-bound biocomposite cell processing kits and devices for cell and gene therapy workflows. Its product portfolio includes the Atract™ T-Cell Activation Kit (for T-cell activation/expansion), the Neptune™ T-Cell Separation Kit (for isolating CD3+ T-cells via gravity-based negative selection), and the Revive™ SVF Isolation Device (a closed automated system for isolating Stromal Vascular Fraction from adipose tissue). The technology eliminates the need for magnetic beads or centrifugation, delivering residue-free cells and reducing processing time and manufacturing cost for therapy developers.
Product overview
Bio-ReCell offers a portfolio of three core magnet-free cell processing products for cell therapy manufacturing: the Atract™ T-Cell Activation Kit (available in V1 and V2 versions with antibody-coated biocomposites for T-cell activation), the Neptune™ T-Cell Separation Kit (gravity-based negative selection for CD3+ cell isolation), and the Revive™ SVF Isolation Device (closed automated system for stromal vascular fraction isolation from adipose tissue). These products are designed for research and clinical applications, eliminating the need for magnets, centrifugation, or residual cleanup, thereby reducing processing times by up to 9 days and manufacturing costs by 10%.
Differentiator
Problem solved
Functional benefit
Products and services
- Atract™ T-Cell Activation Kit Magnet-free T-cell activation reagent using antibody-coated biocomposite particles for robust, residue-free T-cell activation and expansion. Available in V1 (CD3/CD28) and V2 (CD2/CD3/CD28) versions, designed for research and clinical applications including CAR-T therapy development.
- Neptune™ T-Cell Separation Kit Magnet-free, xeno-free T-cell isolation kit using gravity-based negative selection to isolate pure CD3+ populations from PBMCs without centrifugation or magnetic separation. Each kit contains 6x 80 mg of Bio-ReCell Neptune™ biocomposites, 6x strainers, and 1x buffer. Delivers functionally intact cells suitable for downstream applications.
- Revive™ SVF Isolation Device Closed, automated, point-of-care-oriented device for isolating Stromal Vascular Fraction (SVF) from adipose tissue. Automates enzymatic SVF isolation without centrifugation, simplifying GMP processes with cell isolation falling into GMP grade D instead of grades A-B. Designed for regenerative medicine and tissue engineering applications.
Quantifiable outcome
- 9 days reduction in processing times and quality control per batch for T-cell therapy manufacturers
- +2 more outcomes
Companies that use Bio-ReCell
Customer profileSegments3 records
Ideal customer profiles3 records
Bio-ReCell technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature4 records
Bio-ReCell partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and strategic.
- Api Asia Ltd.coreBio-ReCell expanded across Asia-Pacific through strategic partnership with Api Asia. Api Asia represents Bio-ReCell technologies in South Korea, Japan, Taiwan, Thailand, Vietnam, Australia, New Zealand, Indonesia, Malaysia, Philippines, and Singapore, providing researchers and organizations in the region with access to innovative cell processing technologies.
- Ross Biotech, Cytocare, Cell BioasiscoreBio-ReCell strengthened presence in India through partnerships with Ross Biotech, Cytocare, and Cell Bioasis. These distributors support academic institutions, biotechnology companies, contract research organizations, and translational research teams throughout India with local expertise and customer support.
- Cosmo Bio USAcoreCosmo Bio USA serves as official US distributor for Bio-ReCell products. As a bridge between global innovation and the scientific community, Cosmo Bio USA provides researchers with access to Bio-ReCell's advanced cell processing technologies, supporting cell therapy development, translational research, and regenerative medicine applications.
- FilgencoreFilgen became official distributor of Bio-ReCell products in Japan. A well-established trading and manufacturing company serving bioscience and nanoscience research markets, Filgen provides high-quality scientific solutions and technical support for advanced cell therapy and cell processing technologies.
- Caltag MedsystemscoreCaltag Medsystems serves as official distributor of Bio-ReCell products in the United Kingdom. As a well-established supplier to the UK life science sector, Caltag supports researchers, laboratories, and biotechnology organizations with advanced scientific solutions and technical expertise.
- ScaleReadycoreBio-ReCell joined ScaleReady's prestigious G-Rex® Grant Program. ScaleReady is a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf. The collaboration validates and optimizes Bio-ReCell technology across all G-Rex models, developing robust, scalable, and regulatory-compliant processes for T-lymphocyte activation and expansion.
- BIOTEMcoreStrategic collaboration integrating BIOTEM's advanced humanized antibodies into Bio-ReCell's Atract™ T-cell activation kit and Neptune™ T-cell separation kit. This partnership enhances precision, efficiency, and scalability across cell therapy manufacturing processes. BIOTEM provides high added value services for development and production of custom monoclonal antibodies complying with ISO 9001:2015 / ISO 13485:2016 standards.
- AcouSortstrategicBio-ReCell and AcouSort signed Letter of Intent to jointly develop an automated system for clean-up and isolation of stem cells and immune cells from adipose tissue. Partnership combines AcouSort's acoustofluidic technology with Bio-ReCell's cell digestion and isolation capabilities. Initial trial at AcouSort's facility in Lund demonstrated feasibility of using acoustic separation technology on output from Revive™ SVF isolation device.
- GlantreocoreCollaboration integrating Glantreo's functionalized SOLAD™ silica particles into Bio-ReCell's Atract™ T-cell activation kit. Glantreo brings nearly two decades of expertise in developing high-quality nano-featured materials with scalable manufacturing capabilities. The partnership supports delivery of current and future products for cell separation and activation.
- Biobanka popkovnične krvi d.o.o.strategicEU Recovery and Resilience Facility project partner for developing an automated system integrating the entire process of separating mesenchymal stem cells (MSC). Project budget of €512,934.67 with €299,988.37 EU funding. Project duration November 2023 - October 2025.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Bio-ReCell competitors and assessment
Company assessmentBroad incumbents
- Miltenyi Biotec: Global market leader in magnetic-bead cell separation and activation (MACS technology) and the dominant incumbent Bio-ReCell is directly displacing in T-cell and stem cell workflows. Serves the same CAR-T and regenerative medicine customers with established GMP-grade reagents and a broad instrument footprint.
- Cytiva (Danaher): Supplies cell and gene therapy manufacturing tools including cell activation reagents and processing consumables; parent of the Cell and Gene Therapy business where Bio-ReCell advisor Dr. Shannon Eaker spent 11+ years. Comparable in targeting CAR-T developers and CDMOs with GMP-grade ancillary materials.
- Thermo Fisher Scientific (Cell Therapy Services): Through its CTS (Cell Therapy Systems) brand, provides cell processing reagents, media, and instruments for T-cell therapy manufacturing, including magnetic bead-based activation kits. Direct competitor to Atract™ and Neptune™ in the same customer accounts.
- Bio-Techne: Provides GMP cytokines and cell culture reagents for cell therapy manufacturing, and is a parent of the ScaleReady JV (with Fresenius Kabi and Wilson Wolf) that has partnered with Bio-ReCell on G-Rex validation. Comparable in supplying ancillary materials into the same CAR-T manufacturing workflow.
- Lonza Cell & Gene Technologies: Global CDMO and supplier of cell therapy manufacturing services and process development tools, including media and ancillary materials used in T-cell and stem cell workflows. Indirect competitor via the manufacturing services and consumables ecosystem that Bio-ReCell's products plug into.
Direct peers
- CellGenix: Specialist in GMP-grade cell and gene therapy raw materials including cytokines, media, and cell processing reagents for T-cell activation and expansion. Closest pure-play comparator to Bio-ReCell in the cell processing ancillary materials niche.
- Akadeum Life Sciences: Develops buoyancy-based (gas-filled microbubble) cell isolation technology as a magnet-free alternative to magnetic bead separation, directly paralleling Bio-ReCell's magnet-free differentiation thesis in T-cell and immune cell workflows.
- STEMCELL Technologies: Supplies cell isolation kits (EasySep™ magnetic platform) and T-cell activation reagents (ImmunoCult™) widely used in cell therapy research and process development. Direct overlap with Neptune™ and Atract™ in academic and translational cell therapy labs.
- Wilson Wolf Manufacturing: Manufacturer of the G-Rex gas-permeable cell expansion bioreactor that is the platform on which Bio-ReCell is validating Atract™ kits. Strategic technology partner via the ScaleReady JV and the gating ecosystem for Bio-ReCell's T-cell activation products.
Regional players
- Pluristem Therapeutics: Develops placenta-derived stromal cell therapies using proprietary 3D bioreactor manufacturing processes. Comparable to Bio-ReCell's Revive™ SVF isolation value proposition in regenerative medicine cell processing, with overlap in MSC-based therapy workflows.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Bio-ReCell social profiles
Digital presenceBio-ReCell compliance and trust
Trust signalCompliance5 records
Bio-ReCell financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bio-ReCell leadership team
Management profileNumber of profiles
Profiles10 records
Bio-ReCell subsidiaries and ownership
Company hierarchySubsidiaries1 record
Bio-ReCell funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bio-ReCell M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bio-ReCell
What does Bio-ReCell do?
Bio-ReCell develops and sells magnet-free, antibody-bound biocomposite cell processing kits and devices for cell and gene therapy workflows. Its product portfolio includes the Atract™ T-Cell Activation Kit (for T-cell activation/expansion), the Neptune™ T-Cell Separation Kit (for isolating CD3+ T-cells via gravity-based negative selection), and the Revive™ SVF Isolation Device (a closed automated system for isolating Stromal Vascular Fraction from adipose tissue). The technology eliminates the need for magnetic beads or centrifugation, delivering residue-free cells and reducing processing time and manufacturing cost for therapy developers.
Is Bio-ReCell a public or private company?
Bio-ReCell is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Bio-ReCell founded?
Bio-ReCell was founded in 2018. It employs 11 to 50 people.
Where is Bio-ReCell based?
Bio-ReCell is headquartered in London, United Kingdom, in the Europe region.
How does Bio-ReCell make money?
Three revenue lines are on record. T-Cell Activation Kit Sales are the primary driver. The others are T-Cell Separation Kit Sales and SVF Isolation Device Sales.
Who are Bio-ReCell's main competitors?
Broad incumbents on record are Miltenyi Biotec, Cytiva (Danaher), Thermo Fisher Scientific (Cell Therapy Services), Bio-Techne and Lonza Cell & Gene Technologies. Direct peers are CellGenix, Akadeum Life Sciences, STEMCELL Technologies and Wilson Wolf Manufacturing. Pluristem Therapeutics is listed as a regional player.
Does Bio-ReCell have an API?
No public API is recorded for Bio-ReCell.